Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)

NCT03194815 is registered in ClinicalTrials.gov with University of Cambridge as lead sponsor.

NCT NCT03194815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03194815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)
Lead sponsor
University of Cambridge
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 1, 2017
Completion date
April 30, 2027
Enrollment
70 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune encephalitis, psychosis